{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-037605","form_type":"8-K","ticker":"CING","cik":"0001862150","company_name":"Cingulate Inc.","filed_at":"2026-08-13T12:40:15+00:00","discovered_at":"2026-08-13T12:45:05.322925+00:00","generated_at":"2026-08-13T12:45:14.442777+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cingulate Q2 net loss $5.9M, cash $28.4M; CTx-1301 NDA resubmission progress, Prasco deal","bullets":["Cash and cash equivalents $28.4M as of June 30, 2026, up from $11.0M at Dec 31, 2025; runway into mid-2027.","Q2 net loss $5.9M vs $5.0M YoY; six-month net loss $15.2M vs $8.8M; SG&A up 101.5% to $3.9M.","FDA CRL on June 1, 2026 for CTx-1301 NDA requested additional CMC info; no safety/efficacy concerns; resubmission planned.","U.S. Patent No. 12,653,791 issued June 16, 2026 covering CTx-1301, expires Dec 2042.","Signed exclusive distribution agreement with Prasco, LLC on July 21, 2026 for CTx-1301 launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-037605","json":"https://secwatch.observer/filing/0001493152-26-037605.json","markdown":"https://secwatch.observer/filing/0001493152-26-037605.md","text":"https://secwatch.observer/filing/0001493152-26-037605.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226037605/0001493152-26-037605-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226037605/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T12:45:14.442777+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}